Elijah Cummings (D-Md.) asked Valeant to explain price hikes for two heart medications. Such increases were central to the company’s strategy; it borrowed heavily to buy drugs, then sharply raised prices. In the past month, Valeant disclosed it was the su
Much of Valeant’s sales growth has come from aggressive price hikes— which it’s now sworn off—and M&A.
① Limited growth options Relying on takeovers, Valeant has spent relatively little on research and development.